2. Disease Areas
  3. Infection
  4. Fungal Infection
  5. Cryptococcal Infection

Cryptococcal Infection

Cryptococcal infection is a fungal disease caused by Cryptococcus neoformans, primarily affecting immunocompromised individuals, with clinical manifestations ranging from pulmonary and cutaneous involvement to life-threatening cryptococcal meningitis characterized by subacute headache, fever, and altered mental status. Diagnosis relies on cerebrospinal fluid analysis using India ink preparations and cryptococcal antigen testing. Cutaneous cryptococcosis presents as various skin lesions, often resulting from hematogenous spread in disseminated cases, and may follow exposure to environmental sources such as soil, bird droppings, or wood debris. Pulmonary cryptococcosis, which can occur as a primary infection or part of systemic disease, typically affects those with underlying immunodeficiency or chronic lung conditions but may also occur in healthy individuals, presenting with cough, chest pain, dyspnea, fever, and weight loss, though many cases remain asymptomatic.

Cryptococcal Infection (8):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113205
    15-keto-Prostaglandin E2 26441-05-4 ≥99.0%
    15-keto-Prostaglandin E2 (15-keto-PGE2) is an endogenous PGE2 metabolite. 15-keto-Prostaglandin E2 inhibits STAT3 activation by binding to the Cys259 residue of STAT3. 15-keto-Prostaglandin E2 binds to and stabilizes EP2 and EP4 receptors. 15-keto-Prostaglandin E2 inhibits the growth and progression of breast cancer cells. 15-keto-Prostaglandin E2 activates PPAR-γ and promotes fungal growth. 15-keto-Prostaglandin E2 disrupts glomerular vascularization during zebrafish development and reduces the surface area of the glomerular filtration barrier.
    15-keto-Prostaglandin E2
  • HY-179704
    Antifungal agent 141
    Antifungal agent 141, a Phenoxazine (HY-34463) derivative, is an antifungal agent. Antifungal agent shows potent antifungal activity in Cryptococcus neoformans and Candida albicans with MIC values of 2 and 4 µg/mL. Antifungal agent 141 can be used for the research of cryptococcal meningitis.
    Antifungal agent 141
  • HY-186027
    Antifungal agent 152 2225901-81-3
    Antifungal agent 152 (Compound 27) is an antifungal agent. Antifungal agent 152 shows antifungal activity against C. neoformans, C. albicans, C. glabrata with MICs of 4 μg/mL, 16 μg/mL, 16 μg/mL, respectively.
    Antifungal agent 152
  • HY-N19644
    (-)-Oxysporidinone 884604-98-2
    (-)-Oxysporidinone is an antifungal agent. (-)-Oxysporidinone inhibits the growth of Aspergillus fumigatus and Cryptococcus neoformans. (-)-Oxysporidinone can be used in studies related to fungal infections.
    (-)-Oxysporidinone
  • HY-119726B
    Fosmanogepix TFA
    Fosmanogepix TFA (APX001 TFA) is an orally active APX001A (HY-18233) prodrug and antifungal agent. Fosmanogepix TFA is effective against Cryptococcus neoformans, Fluconazole (HY-B0101)-resistant C. auris. Fosmanogepix TFA is effective in the treatment of invasive pulmonary aspergillosis and pulmonary murine mucormycosis.
    Fosmanogepix TFA
  • HY-181784
    Ac-CoA-IN-1
    Ac-CoA-IN-1 is an acyl-AMP phosphate analog and weak inhibitor of Candida albicans acetyl-CoA synthetase 2, with no activity against Cryptococcus neoformans acetyl-CoA synthetase 1. Ac-CoA-IN-1 crystallizes with Cryptococcus neoformans ACS1 enzyme to yield structural insight for inhibitor design. Ac-CoA-IN-1 can be used for the research of fungal infections.
    Ac-CoA-IN-1
  • HY-181101
    Antifungal agent 151 3097563-43-1
    Antifungal agent 151 is a Prp8 intein inhibitor that inhibits the self-splicing process of the Prp8 intein, preventing maturation of the Prp8 protein. Antifungal agent 151 exerts in vitro antifungal activity against Cryptococcus neoformans and Cryptococcus gattii. Antifungal agent 151 can be used for the research of cryptococcus pneumonia.
    Antifungal agent 151
  • HY-180672
    Antifungal agent 145
    Antifungal agent 145 (Compound 14') is a highly effective fungicide. Antifungal agent 145 exhibits MICs against Candida albicans, Candida tropicalis, and Cryptococcus neoformans of 4, 8, and 8 μg/mL respectively. Antifungal agent 145 exerts a potent and rapid bactericidal effect by disrupting the fungal cell membrane, and can effectively inhibit and destroy biofilms. Antifungal agent 145 has improved safety and can be used in antifungal research.
    Antifungal agent 145